Olamoyegun Micheal, Kolawole Babatope, Ajayi Adesuyi A L
Ladoke Akintola University, Ogbomoso, Oyo State, Nigeria.
Obafemi Awolowo University, Ile-Ife, Osun State, Nigeria.
J Pharmacol Pharmacother. 2017 Apr-Jun;8(2):68-73. doi: 10.4103/jpp.JPP_140_16.
To assess the effects of hydrochlorothiazide (HCT) given alone and in combination with an angiotensin-converting enzyme inhibitor (ACEI) on beta-cell function in a negroid population to further explore possible ethnic differences in the effect of antihypertensive drugs on homeostasis model assessment - insulin resistance (HOMA-IR).
A total of 80 newly diagnosed Nigerian essential hypertensive patients were assigned to receive either HCT 25 mg daily or both HCT and lisinopril (Lis; 25/10 mg daily) in an open-label study for 12 weeks. The treatment groups were well matched in clinical and demographic baseline features. Changes in HOMA-IR from baseline to end of study (week 12), fasting plasma glucose (FPG), serum potassium, serum insulin, and blood pressure over the same period were also evaluated.
After 12 weeks, mean delta HOMA-IR (and %) was higher in the HCT monotherapy group; although, this change did not reach statistical significance in both groups -0.1 ± 7.1, = 0.538 (HCT) and 0.6 ± 4.2 = 0.913 (HCT + Lis); an insignificant increase was observed in FPG and serum insulin in both groups, whereas serum potassium decreased in similar fashion. Blood pressure reduction was similar in both groups. Analysis of HOMA-IR change according to gender in response to HCT mono- or combination therapy with Lis showed no significant difference.
HCT monotherapy in hypertensive indigenous Nigerians, was not associated with worse metabolic effects when compared with combination therapy using Lis, an ACEI after 12 weeks. Low-dose thiazide diuretic as first-line antihypertensive medication may be safe in the short-term, further larger and long-term studies are needed to corroborate this finding.
评估单独使用氢氯噻嗪(HCT)以及联合血管紧张素转换酶抑制剂(ACEI)对黑人人群β细胞功能的影响,以进一步探究降压药物对稳态模型评估-胰岛素抵抗(HOMA-IR)作用的可能种族差异。
在一项开放标签研究中,共80例新诊断的尼日利亚原发性高血压患者被分配接受每日25mg HCT治疗,或同时接受HCT和赖诺普利(Lis;每日25/10mg)治疗,为期12周。治疗组在临床和人口统计学基线特征方面匹配良好。还评估了从基线到研究结束(第12周)HOMA-IR的变化、空腹血糖(FPG)、血清钾、血清胰岛素以及同期血压的变化。
12周后,HCT单药治疗组的平均HOMA-IR变化值(及百分比)更高;尽管两组的这一变化均未达到统计学意义——HCT组为-0.1±7.1,P = 0.538,HCT + Lis组为0.6±4.2,P = 0.913;两组FPG和血清胰岛素均有不显著增加,而血清钾以相似方式降低。两组血压降低情况相似。根据性别分析HCT单药或联合Lis治疗时HOMA-IR的变化,未显示出显著差异。
与12周后使用ACEI类药物Lis的联合治疗相比,尼日利亚本土高血压患者接受HCT单药治疗并未产生更差的代谢影响。低剂量噻嗪类利尿剂作为一线降压药物在短期内可能是安全的,需要进一步开展更大规模的长期研究来证实这一发现。